Evidence map›Paper›PMID 28640505›Full record

ArticleEnvironmental and molecular mutagenesis2017

Associations between arsenic (+3 oxidation state) methyltransferase (AS3MT) and N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) polymorphisms, arsenic metabolism, and cancer risk in a chilean population.

Rosemarie de la Rosa, Craig Steinmaus, Nicholas K Akers, Lucia Conde, Catterina Ferreccio, David Kalman, Kevin R Zhang, Christine F Skibola, Allan H Smith, Luoping Zhang and 1 more

Abstract read
In one paragraph

Article in Environmental and molecular mutagenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Arsenic and cancer: Evidence and mechanisms.Advances in pharmacology (San Diego, Calif.) · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Factors Affecting Arsenic Methylation in Contaminated Italian Areas.International journal of environmental research and public health · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Association ofFrontiers in pharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Rosemarie de la RosaSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Craig SteinmausSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Nicholas K AkersSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Lucia CondeSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Catterina FerreccioDepartamento de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de Chile, Advanced Center for Chronic Diseases, ACCDiS, Santiago, Chile.
David KalmanDepartment of Environmental & Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington, DC.
Kevin R ZhangSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Christine F SkibolaSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Allan H SmithSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Luoping ZhangSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
Martyn T SmithSuperfund Research Program, Divisions of Environmental Health Sciences and Epidemiology, School of Public Health, University of California, Berkeley, California.
University of California, Berkeley · USPontificia Universidad Católica de Chile · CLUniversity of Washington · US

Funding

Training CoreP42ES004705 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI MORELLO-FROSCH, RACHEL ADELE · 1987 to 2025
$74.6M
Incident cancer studies in a unique arsenic-exposed area of ChileR01ES014032 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI STEINMAUS, CRAIG M · 2007 to 2018
$3.8M
NIEHS NIH HHS P42 ES004705NIEHS NIH HHS R01 ES014032
6 · The paper itself

Abstract

Inter-individual differences in arsenic metabolism have been linked to arsenic-related disease risks. Arsenic (+3) methyltransferase (AS3MT) is the primary enzyme involved in arsenic metabolism, and we previously demonstrated in vitro that N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) also methylates the toxic inorganic arsenic (iAs) metabolite, monomethylarsonous acid (MMA), to the less toxic dimethylarsonic acid (DMA). Here, we evaluated whether AS3MT and N6AMT1 gene polymorphisms alter arsenic methylation and impact iAs-related cancer risks. We assessed AS3MT and N6AMT1 polymorphisms and urinary arsenic metabolites (%iAs, %MMA, %DMA) in 722 subjects from an arsenic-cancer case-control study in a uniquely exposed area in northern Chile. Polymorphisms were genotyped using a custom designed multiplex, ligation-dependent probe amplification (MLPA) assay for 6 AS3MT SNPs and 14 tag SNPs in the N6AMT1 gene. We found several AS3MT polymorphisms associated with both urinary arsenic metabolite profiles and cancer risk. For example, compared to wildtypes, individuals carrying minor alleles in AS3MT rs3740393 had lower %MMA (mean difference = -1.9%, 95% CI: -3.3, -0.4), higher %DMA (mean difference = 4.0%, 95% CI: 1.5, 6.5), and lower odds ratios for bladder (OR = 0.3; 95% CI: 0.1-0.6) and lung cancer (OR = 0.6; 95% CI: 0.2-1.1). Evidence of interaction was also observed for both lung and bladder cancer between these polymorphisms and elevated historical arsenic exposures. Clear associations were not seen for N6AMT1. These results are the first to demonstrate a direct association between AS3MT polymorphisms and arsenic-related internal cancer risk. This research could help identify subpopulations that are particularly vulnerable to arsenic-related disease. Environ. Mol. Mutagen. 58:411-422, 2017. © 2017 Wiley Periodicals, Inc.

Indexed as

Genetic Predisposition to DiseasePolymorphism, GeneticAgedArsenicChileFemaleGene FrequencyHumansLinkage DisequilibriumMaleMethyltransferasesMiddle AgedNeoplasmsOxidation-ReductionRisk FactorsSite-Specific DNA-Methyltransferase (Adenine-Specific)ArsenicAS3MT protein, humanMethyltransferasesN6AMT1 protein, humanSite-Specific DNA-Methyltransferase (Adenine-Specific)arsenic metabolismAS3MTcancerN6AMT1polymorphism

Identifiers

PMID28640505
PMCPMC5515250
OpenAlexW2652286378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.